Maria L Amaya

10PUBLICATIONS
110CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Molecular medicineHaematological tumoursMedical devices
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

|Feb 13, 2026
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia.

Michael K Jones, Jesse Sanchez, Megan Connor

|Nov 14, 2025
Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.

Tianyi Ling, Cristiana O'Brien, Jonathan R St-Germain

|Sep 26, 2025
siRNA Mediated Genetic Perturbation of Primary Human Leukemia Stem and Progenitor Cells.

Anagha Inguva, Hunter Tolison, Jeremy Rahkola

|May 21, 2025
Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study.

Curtis A Lachowiez, Mael Heiblig, Gaspar Aspas Requena

|Jan 30, 2025
A novel therapy with a rational design for AML.

Maria L Amaya

Pageof 2

Frequent Collaborators

6 joint publications

Daniel A Pollyea

4 joint publications

Amanda Winters

3 joint publications

Christine McMahon

2 joint publications

Sarah Staggs